So how much does it cost for an EU pharmaceutical company to break into the North American market?
Ipsen can answer that question: three deals and ~$450M.
First, Ipsen acquired the shares of Tercica (TRCA) they didn’t own.
Second, they bought the US subsidiary of the UK based Vernalis (VNLS) and the rights to Apokyn (apomorphine)and finally, they nabbed all OBI-1 (may the force be with them) assets from Octagen.
You can find all the nitty gritty details here.